Abstract Declining physical function is a major health problem for older adults as it is associated with multiple comorbidities and mortality. Exercise has been shown to improve physical function, though response to exercise is variable. Conversely, drugs targeting the renin-angiotensin system (RAS) pathway, including angiotensinconverting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs), are also reported to improve physical function. In the past decade, significant strides have been made to understand the complexity and specificity of the RAS system as it pertains to physical function in older adults. Prior findings have also determined that interactions between antihypertensive medications and exercise may influence physical function above and beyond either factor alone. We review the latest research on RAS, exercise, and physical function for older adults. We also outline future research aims in this area, including genetic influences and clinical phenotyping, for the purpose of maintaining or improving physical function through tailored treatments.
Introduction
Physical function is an important predictor of health outcomes in older adults. The ability to perform basic physical function tasks is an important component of health-related quality of life (Muszalik et al. 2011 ) and a predictor of hospitalization, surgical outcomes, and mortality (Penninx et al. 2000; Dumurgier et al. 2009; Afilalo et al. 2010; Studenski et al. 2011) . Accordingly, maintaining physical function is critical to the preservation of health and the well-being of older adults. In the USA, nearly half of the 37.3 million persons aged ≥65 years report having one or more physical limitations in performing essential daily tasks (Seeman et al. 2010) . The adverse outcomes associated with these limitations have created a significant burden on health-care systems, which is likely to become more substantial given that older adults represent the fastest-growing segment of the population (US Census 2009). As a result, the development of methods to maintain the health and independence of older persons is an important public health goal.
A number of studies have shown physical exercise to have beneficial effects on the physical function of older adults (Cress et al. 1999; Brown et al. 2000; Miszko et al. 2003; Nelson et al. 2004; LIFE Study Investigators et al. 2006) . However, to date, no pharmacologic therapies have proven to be effective in attenuating agerelated functional decline. An efficacious pharmacologic intervention could have significant clinical impact since such regimens typically require minimal effort on the part of patients-an important point given that the initial effort to begin an intervention program is a primary barrier to lifestyle-based treatments (Lees et al. 2005) . Several years ago, Carter et al. (2005) reported on the potential for angiotensin-converting enzyme inhibitors (ACEi) to improve body composition and physical performance among older adults. In the years following, scientists have made significant strides in the basic understanding of renin-angiotensin system (RAS) physiology, as well as the effects of RAS modulation on physical performance. Collectively, these studies have increased understanding and raised new questions regarding the potential of RAS-modulating drugs in preventing age-related disability. The objective of the present review is to concisely highlight these recent developments and highlight key remaining gaps in the literature related to determining the potential utility of ACEi, as well as angiotensin receptor blockers (ARBs), in the preservation of physical function and prevention of disability in older persons.
RAS pathway and physiology: recent developments
Conventional RAS pathway and introduction of Ang (1-7) axis Classically, RAS has been described as the progressive cleavage of liver-secreted angiotensinogen into the peptide angiotensin I (Ang I). Kidney-secreted renin is necessary for the cleavage, which itself is inhibited by atrial and brain natriuretic peptides (ANP and BNP, respectively). When present, Ang I is converted by angiotensin-converting enzyme (ACE) into the peptide angiotensin II (Ang II), which acts on angiotensin II receptor type 1 (AT1) (Fig. 1(A) ). ACE also breaks down the peptide bradykinin ( Fig. 1(B) ), a key vasodilatory peptide. Ang I can also be converted to Ang II by the chymase family of enzymes, although the mechanisms of this pathway are considered separate from the conventional RAS pathway (Balcells et al. 1997; Miyazaki and Takai 2006; Lorenz 2010) .
Angiotensin II is both formed in, and acts in, a large variety of tissue types and is involved in many cellular processes other than blood pressure regulation-most notably cell growth and extracellular matrix formation (de Gasparo et al. 2000) . Also important is that Ang II and nitric oxide signaling pathways reportedly overlap and that, with ACE inhibitors, there is a protective attenuation of ROS production, inflammation signaling pathways, and cell death pathways (Marzetti et al. 2011) . Over a decade ago, a second ACE form was discovered (ACE2), which acts upon Ang II to make Ang (1-7) (Donoghue et al. 2000) . Since that time, research has elucidated details of an adjunctive RAS axis, where ACE2 and other endopeptidases (neprilysin) catalyze Ang I or II conversion into the peptide angiotensin (1-7) (Velez et al. 2009 ), which acts on the Mas (AT 7 ) receptor to induce cardioprotective mechanisms (Santos 2014 ; Fig. 1(C) ). In contrast to the Ang II-AT1 axis, Ang (1-7) signaling is connected to downstream vasodilation action, which counteracts the hypertensive effects of AT1 signaling. The Ang (1-7) axis is significant due to the plieotropic effects of antihypertensive medications like ACE inhibitors (ACEi) and angiotensin receptor blockers (ARBs) (Passos-Silva et al. 2013) . For example, both AT1 signaling inhibition and Mas signaling activation induce antihyperglycemic effects in humans, highlighting commonalities between downstream signal transduction of Ang (1-7) and insulin. The Ang (1-7) axis is also involved in antiangiogenic, antifibrotic, and anti-inflammatory properties (Machado et al. 2001; Katovich et al. 2008; Passos-Silva et al. 2013) . Research has also eluded to detrimental axis triggered when ACE breaks down Ang ( 1 -7 ) i n t o A n g ( 1 -5 ) , w h i c h i n h i b i t s t h e cardioprotective mechanisms of the Ang (1-5) axis (Schindler et al. 2007 ). However, research on mechanisms and clinical effect of this axis is limited. While the classical RAS pathway has been vastly studied, in this review, we will focus on how it has been investigated in muscle and physical function and using different antihypertensive drugs to determine novel strategies to improve patient care.
Local tissue-specific RAS Systemic RAS involves reaction of circulating enzymes and substrates derived from characteristic organs (Cushman et al. 1989 ). However, the independent RAS exists localized within specific tissues (Abadir et al. 2012) . Notably, local RAS have been identified in a number of tissues including, but not limited to, cardiac, nervous, renal, and gastrointestinal (Paul et al. 2006; Bader and Ganten 2008) . While possessing the same biochemical activity as circulating systems, local RAS effectors vary in response to physiological perturbation. Therefore, local effects of RAS-modifying interventions may occur despite similar systemic exposure to the drug. Furthermore, the activity and structure of local RAS change with age. For example, compared to younger mice, Ang II receptor density is decreased within skeletal muscle mitochondria of older mice (Abadir 2011) . Chronic Ang II elevation without hypertension has been shown to produce age-related cardiomyopathy in transgenic mice, suggesting specificity to cardiac muscle (Domenighetti et al. 2005) . Related to renal RAS, urinary Ang II and Ang (1-7)-as well as protein excretion-have been found to increase in older versus younger Fischer-344 rats (Gilliam-Davis et al. 2007 ).
Renal RAS also appears to undergo age-related influence by other local systems, most notable brain RAS.
Glial angiotensinogen-deficient transgenic rats have demonstrated lower systolic blood pressure, lower serum leptin, and lower glucose-insulin index with aging compared to normal aging animal models (Kasper et al. 2005 (Kasper et al. , 2006 . Baroreflex sensitivity is also preserved in older glial angiotensinogen-deficient transgenic rats, demonstrating contributions of brain RAS to agerelated cardiac function decline (Arnold et al. 2008 (Arnold et al. , 2013 . Finally, age-related comorbid conditions can have significant influence on the structure of local RAS, as diabetes has been associated with increased intracellular RAS activity and subsequent fibrosis within cardiac muscle (Singh et al. 2008) .
Skeletal muscle accounts for~40 % of total body mass and is the primary tissue responsible for movement (Smith and Muscat 2005) . As such, skeletal muscle is a critical tissue for the regulation and maintenance of physical function. In addition to the systemic RAS, both animal and human studies have demonstrated the existence of a local RAS within skeletal muscle tissue (Reneland and Lithell 1994; Jones and Woods 2003) . These studies have identified several important physiologic effects for the local skeletal muscle RAS. For example, muscle RAS may be integral to the muscle formation, as Ang II inhibition has been associated with decreased capillary and myoblast formation Johnston et al. 2011) . Emerging evidence Fig. 1 Renin angiotensin pathway. Simplified overview of the RAS. A Conventional RAS pathway: angiotensinogen is cleaved by renin to form Ang1, is converted to angiotensin II peptide (Ang II) by angiotensin-converting enzyme (ACE), and acts on angiotensin II receptor type 1 (AT1) to cause vascular dysfunction, inflammation, and oxidative damage. B Bradykinin breakdown: vasodilatory peptide broken down by ACE. C Adjunctive RAS axis: angiotensin-converting enzyme 2 (ACE2) converts Ang II to peptide angiotensin (1-7) [Ang (1-7)], acts on the Mas (AT7) receptor, and induces cardioprotective mechanisms. D Ang (1-7) breakdown: ACE hydrolyzes Ang (1-7) to Ang (1-5), which inhibits cardioprotective mechanisms (Schindler et al. 2007) also suggests muscle RAS differentially influences skeletal muscle based on fiber type . A study by Westerkamp and Gordon (2005) found Ang II attenuation inhibited satellite cell response to overload of the soleus, but not plantaris, muscle of Sprague Dawley rats, suggesting a specificity to slow-versus fast-twitch muscle fibers. Still, despite these findings, the full extent of physiologic impact of the local RAS on muscle function remains undetermined. Likewise, a paucity of evidence exists to determine age-related effects to local muscle RAS. Future investigations are warranted to determine how advanced age influences activity of skeletal muscle and other local RAS. Studies are also needed to determine how these local systems interact with the systemic RAS and may contribute to changes in physical function in advanced age.
Angiotensin-converting enzyme inhibitors and physical function
Angiotensin-converting enzyme inhibitors (ACEi) prevent Ang I to Ang II conversion by inhibiting ACE activity, effectively preventing the constriction of blood vessels, and lowering blood pressure. Thus, ACEi are widely utilized for managing hypertension. Moreover, ACEi-either independently or in combination with other drugs-have shown effects for a variety of other conditions including acute myocardial infarction, cardiac failure, diabetic nephropathy, and cognitive decline (McFarlane et al. 2003; Brugts et al. 2009; Sink et al. 2009 ). These benefits manifest at least partially as a result of improved endothelial function and reduced oxidative stress and inflammation (Krysiak and Okopień 2008; Ismail et al. 2010 ). While such beneficial effects on cardiovascular outcomes are well documented, the ability of ACEi to improve physical function remains somewhat in question.
A number of preclinical studies have suggested that ACEi may have a protective effect in preserving muscle strength, endurance, and body composition in late life (Coirault et al. 1999; Carter et al. 2005) . Several studies have also evaluated the potential utility of ACEi for persevering physical function in humans; however, the findings have been mixed. In a randomized controlled trial of ACEi effects, functionally impaired seniors on ACEi demonstrated 6-min walk test times equivalent to the improvements seen after 6 months of exercise training (Sumukadas et al. 2007 ). Continuous ACEi use has also been associated with attenuated 3-year rates in decline of muscle strength and walking speed compared to intermittent or alternative antihypertensive medication (Onder et al. 2002) . Conversely, a recent clinical trial of older individuals at high cardiovascular risk showed that physical function was similar after 6 months of ACEi administration compared to placebo . A large observational study of older women also found that ACEi administration was not associated with frailty incidence (Gray et al. 2009 ). In other cases, ACEi have been shown to be associated with overall weight maintenance but not muscle strength maintenance (Schellenbaum et al. 2005) .
Multiple factors may influence the capacity for ACEi to influence physical function, including the health of the cardiovascular system . The complexity of discerning ACEi effects is also increased by the possibility of multiple mechanisms. For example, endothelial function improves with ACEi, and the resultant improvements in blood flow and/or glucose delivery may, therefore, be associated with improvements in muscle function (Henriksen and Jacob 2003) . Further, associations between ACE and body composition may underlie improved physical function mechanisms. For example, older adults taking ACEi have been found to have greater lean body mass in the lower extremities (Di Bari et al. 2004) . By contrast, common ACE-related genetic polymorphisms in older men (e.g., ACE I/D gene, angiotensinogen M235T gene, AT1 A1166C gene) are associated with a greater likelihood of being overweight or having higher abdominal adiposity (Strazzullo et al. 2003) . Finally, insulin-like growth factor-1 (IGF-1) may mediate the relationship between body composition and physical function. Muscle wasting related to Ang II has been attributed to decreased IGF-1 (Song et al. 2005) , and in older adults using ACEi, IGF-1 is higher than those not taking ACEi (Maggio et al. 2006; Giovannini et al. 2010 ).
ARBs and physical function
Like ACEi, ARBs are traditionally used to treat hypertension and have similar downstream effects, albeit through different mechanisms. While ACEi and Ang (1-7) inhibit Ang I to Ang II conversion and subsequent bradykinin breakdown, ARBs work directly by inhibiting ligand binding to the AT 1 receptor. ARBs vary in pharmacokinetic properties and receptor affinity; however, all drugs work by competing with Ang II for receptor binding (Burnier 2001) . Like ACEi, ARBs have shown effects for conditions other than hypertension that are pertinent to older adults, including heart failure, stroke, retinal protection, and diabetes (Cernes et al. 2011) . A recent study by Li et al. (2010) found ARBs to be associated with a reduced incidence and progression of cognitive decline, which was not observed with ACEi. And while ARBs have comparable efficacy to ACE inhibitors, they generally do not face the same potential issue of intolerance (Grothusen et al. 2009 ).
As with ACEi, ARB administration may directly or indirectly improve physical function in the elderly (Carter 2011 ). In the case of metabolic syndrome, ARBs decrease the pressor response to exercise (Nashar et al. 2004 ). In patients with severe congestive heart failure, ARBs reportedly improve exercise capacity (Hamroff et al. 1999 ). More recent clinical trials have extended these results. For example, 4 weeks of ARB treatment improved diastolic heart failure patients' tolerability to exercise (Kato et al. 2008) , while 12 months of ARB treatment improved exercise capacity in patients with peripheral artery disease (Zankl et al. 2010) . Moreover, ARB use may act synergistically with exercise to improve blood pressure, thereby improving overall health. For example, in a recent clinical trial, exercise alongside ARB administration was shown to improve blood pressure of patients with chronic obstructive pulmonary disease, whereas exercise alone could not (Marquis et al. 2008) .
The mechanisms by which ARBs improve physical function are less understood. In animals, long-term ARB administration improves aerobic exercise ability through a mechanism dependent on the PPAR-δ/AMPK pathway (Feng et al. 2011) . However, other studies highlight negative tissue-specific effects of ARBs on exercise performance. For example, ARB injection into the right lateral cerebral ventricle, but not injection peripherally, increased thermogenesis in rats subjected to exhaustive training (Leite et al. 2006) as well as oxygen consumption demands (Leite et al. 2007) , thereby reducing performance. These effects may be due in part to disruption of AT1 signaling and downstream influence on serotonin and dopamine secretion in select regions of the brain (Leite et al. 2010) . Further, ARB effects are not limited to the AT1 receptor. Rodrigues et al. (2007) found that antagonizing angiotensin II effects on the medullary AT2 receptor of hypertensive rats diminished the hypotensive effects of exercise, which implicate the AT2 arm of the brain RAS in managing blood pressure. Moreover, differential ARB effects occur, depending on location of the AT2 receptor blockade in the medulla (Tedesco and Ally 2009) , which highlights both the complexity of this system and current limitations in exploiting its dynamics with ARBbased clinical treatments.
ACEi-exercise interaction
Prior suggestions that ACEi improves physical function have led to more recent studies investigating potential moderating effects of ACEi on exercise response. In previous animal work, ACEi administration was found to have no effect on endurance time, oxidative capacity, or mitochondrial function in sedentary rats (Bahi et al. 2004) . Habouzit et al. (2009) replicated this lack of effect in sedentary rats. However, the same study also reported enhanced running capacity in rats that were endurance trained and administered ACEi compared to those only endurance trained (Habouzit et al. 2009 ). Specific to older animals, preliminary indication is that ACEi administration enhances exercise tolerance above and beyond exercise use alone (Carter et al. 2012) . Moreover, the combination of exercise and ACEi has been linked to physiologic changes related to physical function such as improved capillary density and increased type 1 fiber percentage (Kanazawa et al. 2006; Guo et al. 2010) .
Emerging research suggests that such an ACEi-exercise interaction in late life may translate to humans. Buford et al. (2012) retrospectively examined the effects of chronic exercise on physical function in seniors. Increased exercise response (i.e. changes in walking speed, standing balance, chair-rise ability) was observed in older adults administered ACEi, compared to individuals either not using antihypertensive medication or on alternative antihypertensive medications (Buford et al. 2012) . However, a more recent study using a prospective design did not report enhanced exercise response after 20 weeks of ACEi administration (Sumukadas et al. 2014 ). However, several key questions remain to be answered. For instance, in the latter study, an indicator of aerobic capacity was chosen as the primary indicator of function but the training regimen did not include a component specifically designed to improve aerobic capacity. Additionally, the inclusion of both antihypertensive and non-hypertensive individuals, as well as participant use of a variety of concomitant medications, may have also limited the ability to detect differences between groups. Future studies are necessary to determine the relative influence of these potentially confounding factors.
ARB-exercise interaction
ARBs may also moderate the influence of exercise on physical function, much like ACEi, and these interactions have been observed in animal models. Combining ARBs with exercise has conferred 1) the best renoprotective effects in a rat model of diabetic nephropathy (Tufescu et al. 2008) and 2) protection against insulin resistance induced by high fat diet (Wang et al. 2012) . However, continual eccentric contraction training in conjunction with ARBs was found to prevent gains in muscle mass and contractile force, suggesting that ARBs may have some negative tissue effects (McBride 2006) . Similarly, oral ARB administration was associated with suppression of exercise-induced hippocampal neurogenesis in rats (Mukuda and Sugiyama 2007) .
To date, data regarding an interaction between ARBs and exercise in humans is sparse. One trial comparing ARBs to calcium channel blockers in hypertensive patients found ARBs to attenuate indicators of exerciseinduced inflammatory response and thrombogenic factor activation (Liakos et al. 2012) . However, similar interactions are not universal. For individuals with left ventricle hypertrophy (Gerdts et al. 2006) or right ventricle dysfunction (Dore et al. 2005) , exercise capacity was not improved with ARB treatment. Moreover, disease states like insulin resistance may be more responsive to ACEi. Unlike ARBs, application of ACEi in animals facilitates a return to the normal state of glucose transport. This differential effect is mechanistically related to the ability of ACE inhibitors and/or Ang (1-7) to modulate bradykinin-mediated signaling by preventing its degradation by ACE (Fig. 1(B) ) .
Genetic research of RAS, as it pertains to physical function, has focused primarily on a variant characterized by insertion (I) or the deletion (D) of a 287-bp region of DNA (I/D allele) in the ACE gene locus (Heled et al. 2004; Puthucheary et al. 2011; de Souza et al. 2013) . In Caucasians, nearly 50 % variation of ACE in circulating serum is attributed to the I/D variant (Rigat et al. 1990 ). Moreover, II genotype of the ACE gene has been associated with lower ACE levels, and the ID and DD genotypes with intermediate and higher ACE levels, respectively (Rigat et al. 1990 ). The ACE I/D genetic variant is also purported to play a role in cardiovascular disease processes. Specifically, the DD genotype has been associated with increased Ang II due to increases in ACE, resulting in predisposition to cardiovascular dysfunction (Yanai et al. 1996; Wang et al. 2007 ). However, an ACE II genotype with lower ACE levels has shown to be less of an indicator of cardiovascular problems (Bauters and Amouyel 1998) . In addition, the ACE I/D variant has been linked to variability in insulin sensitivity. Dengel et al. (2002) found that homozygous genotypes (II and DD) were less sensitive to insulin as compared to the ID genotype and that exercise improved insulin sensitivity in the II genotype as compared to the ID or DD genotypes.
Multiple studies have ascertained a link between ACE I/D genetic variant and either training and/or exercise response. Early work by Montgomery et al. (1998) found that high-altitude mountain climbers possessing the I allele had enhanced ascent endurance compared to those without the allele. In the same study, soldiers with I allele demonstrated higher weightlifting endurance compared to those without. Similarly, Fig. 2 Conceptual model of individual influences on exercise response. Age, genetic, exercise, and antihypertensive pharmacotherapy (ACEi), as well as mediation/moderation among these factors, influence exercise response capacity. Improved understanding of factors underlying exercise response could assist in the development of tailored treatments for older adults to optimize improvements in physical function Myerson et al. (1999) observed increased frequency of the I allele in Olympic endurance runners compared to athletes from non-endurance sports. Since that time, research has elucidated a differential influence of the I and D alleles on exercise performance. Specifically, the I allele has been associated with more long-term endurance sports like long-distance running or triathlon, while the D allele has been associated with more short-term and/or strength-related sports like competitive swimming and weightlifting (Puthucheary et al. 2011) . Along the same lines, the D allele has been associated with training-related growth of cardiac muscle compared to the I allele (Puthucheary et al. 2011 ).
Compared to athletes, age-related examination of the ACE I/D genetic variant and exercise response is underinvestigated. However, a recent publication by Buford et al. (2014) suggests that ACE I/D genotype regulates changes in physical function after long-term exercise training in older adults. Specifically, those with the II genotype demonstrated impaired functional responses to regular exercise compared to those with the ID or DD genotype. These findings are similar to those of Kritchevsky et al. (2005) who reported that the II genotype was associated with an increased risk of incident mobility limitation among physically active, but not sedentary, older adults. Notably, subsequent training studies appeared to indicate, as in younger individuals, a genotype effect that was dependent on the mode of exercise utilized. For instance, Giaccaglia et al. (2008) reported that, while responses were robust among DD carriers, older adults with the II genotype did not experience significant increases in knee extensor strength following 18 months of resistance training. In contrast, however, Defoor et al. (2006) reported that improvements in aerobic power were greatest in II carriers following 3 months of aerobic training. Though more research is needed to provide clarity in this area, the mode of exercise appears to have an important influence on functional responses among individuals with particular genotypes. Moreover, future research may ascertain the extent to which genetics mediate or moderate associations between antihypertensive medication (i.e., ACEi or ARBs) and exercise responsiveness for older adults.
Conclusions and future directions
In the present review, we highlight the intricate network between aging, physical function, genetics, and antihypertensive pharmacotherapies. Collectively, these factors appear to be influential in the exercise response capacity of older adults and, in turn, clinical care (Fig. 2) . Accounting for factors underlying exercise response capacity may eventually provide a clinical phenotype, which can be translated to treatment tailored to the individual, for the purpose of improving physical function. However, research is yet to advance this significantly toward the realm of personalized medicine. Traditionally, publications have examined the effect of ACEi or ARBs on physical function without accounting for the influence of genetics. To our knowledge, there has not been a systematic study to evaluate all variables in a single study. Future research should aim to taper the misappropriation of different drugs and identify the correct treatment (exercise regimen and/or HTD) based on individual factors. This type of personalized treatment has the potential to both improve quality of life and prolong life through enhancement of physical function.
